Antitrust Antitrust

US FTC says Teva, Mylan, Abbvie, seven other drugmakers could face Section 5 investigation over improper patents

By Chris May
  • 07 Nov 2023 22:29
  • 07 Nov 2023 22:44
Drug giants Teva, Mylan, Abbvie and seven other companies hold more than 100 improperly listed patents for brand-name pharmaceutical products that may be driving up drug prices, the US Federal Trade Commission said today.
The agency’s action follows a September policy statement putting brand-name drugmakers “on notice” that they could

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News